Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
-
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
-
Olema Oncology to Participate in Upcoming Investor Conferences
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)